News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth
Chintan Shivir has provided a platform to hold discussions with higher officials and experts, which will help in evolving better practices of premier health institutions like AIIMS
Unfortunate to see PM’s ‘Make in India’ dream being bulldozed
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Marks the World Head & Neck Cancer Day at the OCTF Conference
Uses a simple mechanical approach for removing intrauterine tissues
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Subscribe To Our Newsletter & Stay Updated
